Optimum management of overactive bladder: Medication vs Botox® vs InterStim® vs Urgent® PC

Urology Practice

Volumn 1, Issue 1, 2014, Pages 7-12

  Chancellor, Michael B ^a   Levanovich, Peter ^a   Rajaganapathy, Bharathi Raja ^a   Vereecke, Andrew J ^a  

^a OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

Author keywords

Cholinergic antagonists; Mirabegron; OnabotulinumtoxinA; Overactive; Surgery; Urinary bladder

Indexed keywords

BOTULINUM TOXIN A; DARIFENACIN; DIGOXIN; FESOTERODINE; MIRABEGRON; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE; TROSPIUM; UNCLASSIFIED DRUG;

ANTICHOLINERGIC EFFECT; ARTICLE; BACTERIURIA; BLADDER NECK STENOSIS; COGNITIVE THERAPY; DYSURIA; HUMAN; IMPLANTED PERIPHERAL NERVE STIMULATOR; MEDICAL DEVICE COMPLICATION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NON IMPLANTABLE URINE INCONTINENCE ELECTRICAL STIMULATOR; OVERACTIVE BLADDER; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESIDUAL URINE; SACRAL NERVE STIMULATION; SYSTEMATIC REVIEW (TOPIC); URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; URINE RETENTION;

EID: 84904245881     PISSN: 23520779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urpr.2014.02.004     Document Type: Article

References (23)

1. Gormley E.A., Lightner D.J., Burgio K.L., et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. JUrol 2012, 188:2455.
2. Chancellor M.B., Patel V., Leng W.W., et al. OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. Neurology 2013, 81:841.
3. Yeaw J., Benner J.S., Walt J.G., et al. Comparing adherence and persistence across 6 chronic medication classes. JManag Care Pharm 2009, 15:728.
4. Buser N., Ivic S., Kessler T.M., et al. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol 2012, 62:1040.
5. Nitti V.W., Auerbach S., Martin N., et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. JUrol 2013, 189:1388.
6. U.S. Food and Drug Administration: Drug Approval Package, Myrbetriq (mirabegron) Extended Release Tablets 2012.
7. Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA 2011, 305:89.
8. Nitti V.W., Dmochowski R., Herschorn S., et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. JUrol 2013, 189:2186.
9. Full Prescribing Information, OnabotulinumtoxinA (BOTOX) 2013.
10. Medtronic, Inc.: Medtronic InterStim® Therapy Implant Manual 2006.
11. Schmidt R.A., Jonas U., Oleson K.A., et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. JUrol 1999, 162:352.
12. Hassouna M.M., Siegel S.W., Nyeholt A.A., et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. JUrol 2000, 163:1849.
13. Leong R.K., De Wachter S.G., van Kerrebroeck P.E. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review. Urol Int 2010, 84:245.
14. Groen J., Blok B.F., Bosch J.L. Sacral neuromodulation as treatment for refractory idiopathic urge urinary incontinence: 5-year results of a longitudinal study in 60 women. JUrol 2011, 186:954.
15. Brazzelli M., Murray A., Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. JUrol 2006, 175:835.
16. Herbison G.P., Arnold E.P. Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. Cochrane Database Syst Rev 2009, 2:CD004202.
17. Peters K.M., Carrico D.J., Perez-Marrero R.A., et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. JUrol 2010, 183:1438.
18. Percutaneous tibial nerve stimulation for the treatment of voiding dysfunction. Technol Eval Cent Assess Program Exec Summ 2011, 25:1.
19. Burton C., Sajja A., Latthe P.M. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn 2012, 31:1206.
20. Chen H.W., Bercik R.S., Werner E.F., et al. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder. JUrol 2012, 187:178.
21. Staskin D.R., Peters K.M., MacDiarmid S., et al. Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care. Curr Urol Rep 2012, 13:327.
22. Peters K.M., Carrico D.J., MacDiarmid S.A., et al. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study. Neurourol Urodyn 2013, 32:24.
23. Monga A.K., Tracey M.R., Subbaroyan J. Asystematic review of clinical studies of electrical stimulation for treatment of lower urinary tract dysfunction. Int Urogynecol J 2012, 23:993.